Literature DB >> 18384628

Molecular and histological markers in urothelial carcinomas of the upper urinary tract.

Stephanie Eltz1, Eva Comperat, Olivier Cussenot, Morgan Rouprêt.   

Abstract

Urothelial cell carcinomas (UCCs) are one of the most common types of malignancies. Recently, different mechanisms of carcinogenesis, as well as discrepancies in the natural history of urothelial cancers of the bladder and of the upper urinary tract (UUT), have been identified. As a result several teams have focused on specific markers in UUT-UCCs, a very rare type of cancer. This review gives a brief overview on the current markers of interest. Microsatellite instabilities (MSI) are independent molecular makers for prognosis. In addition, MSI can help detect a germline mutation and therefore allows for the detection of possible hereditary cancers. The loss of proteins of the mismatch repair system can also facilitate the detection of a germline mutation but should be followed by DNA sequencing. Epithelial cadherin has been shown to be an independent marker of prognosis, as well as hypoxia-inducible factor-1alpha (HIF-1alpha) and telomerase RNA component. Furthermore HIF-1alpha is significantly associated with the grade and pattern of growth and the telomerase RNA component could possibly also be used in diagnosis. The active form of the L-type amino acid transporter 1 (LAT1) was a significant prognostic marker in univariate analysis only. There are contrasting studies on the significances of p27 and Ki-67 as prognostic markers in UUT-UCCs. MET is a factor that correlates with vascular invasion of invasive cancer and bcl-2 oncoprotein correlates with stage. The ongoing identification of these markers might help to find specific treatments tailored to the molecular pattern of each tumour. Therefore a subgroup of patients with a higher risk of recurrence could be identified as well as patients that could benefit from minimal invasive surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18384628     DOI: 10.1111/j.1464-410X.2008.07659.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

Review 1.  [Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors].

Authors:  M Rink; M Adam; J Hansen; F K Chun; S A Ahyai; M Remzi; T Schlomm; O Engel; R Heuer; C Eichelberg; M Fisch; R Dahlem; S F Shariat
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

2.  Divergent squamous differentiation in upper urothelial carcinoma-comparative clinicopathological and molecular study.

Authors:  Ljubinka Jankovic Velickovic; Zana Dolicanin; Takanori Hattori; Ivana Pesic; Biljana Djordjevic; Mariola Stojanovic; Jablan Stankovic; Milan Visnic; Vladisav Stefanovic
Journal:  Pathol Oncol Res       Date:  2010-12-02       Impact factor: 3.201

Review 3.  Prognostic factors for upper urinary tract urothelial carcinoma.

Authors:  Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

Review 4.  Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.

Authors:  David R Yates; James W F Catto
Journal:  World J Urol       Date:  2012-09-18       Impact factor: 4.226

5.  Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth.

Authors:  Zongqing Tan; Matthew Wortman; Kelsey L Dillehay; William L Seibel; Chris R Evelyn; Shanna J Smith; Linda H Malkas; Yi Zheng; Shan Lu; Zhongyun Dong
Journal:  Mol Pharmacol       Date:  2012-03-07       Impact factor: 4.436

6.  Risk stratification model, including preoperative serum C-reactive protein and estimated glomerular filtration rate levels, in patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy.

Authors:  Shuichi Morizane; Tetsuya Yumioka; Noriya Yamaguchi; Toshihiko Masago; Masashi Honda; Takehiro Sejima; Atsushi Takenaka
Journal:  Int Urol Nephrol       Date:  2015-06-24       Impact factor: 2.370

Review 7.  L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.

Authors:  Qian Wang; Jeff Holst
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

Review 8.  Predictive factors of recurrence and survival of upper tract urothelial carcinomas.

Authors:  Grégory Verhoest; Shahrokh F Shariat; Thomas F Chromecki; Jay D Raman; Vitaly Margulis; Giacomo Novara; Christian Seitz; Mesut Remzi; Morgan Rouprêt; Douglas S Scherr; Karim Bensalah
Journal:  World J Urol       Date:  2011-06-17       Impact factor: 4.226

9.  Identification of differently expressed genes in chemical carcinogen-induced rat bladder cancers.

Authors:  Guangfu Chen; Franky L Chan; Xu Zhang; Peter S F Chan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

10.  Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas.

Authors:  Hale Deniz; Metin Karakök; Faruk Yagci; Muhammet Emin Güldür
Journal:  Int Urol Nephrol       Date:  2009-05-30       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.